| Structural highlights
Publication Abstract from PubMed
Gluco-azoles competitively inhibit glucosidases by transition-state mimicry and their ability to interact with catalytic acid residues in glucosidase active sites. We noted that no azole-type inhibitors described, to date, possess a protic nitrogen characteristic for 1 H-imidazoles. Here, we present gluco-1 H-imidazole, a gluco-azole bearing a 1 H-imidazole fused to a glucopyranose-configured cyclitol core, and three close analogues as new glucosidase inhibitors. All compounds inhibit human retaining beta-glucosidase, GBA1, with the most potent ones inhibiting this enzyme (deficient in Gaucher disease) on a par with glucoimidazole. None inhibit glucosylceramide synthase, cytosolic beta-glucosidase GBA2 or alpha-glucosidase GAA. Structural, physical and computational studies provide first insights into the binding mode of this conceptually new class of retaining beta-glucosidase inhibitors.
Gluco-1 H-imidazole: A New Class of Azole-Type beta-Glucosidase Inhibitor.,Schroder SP, Wu L, Artola M, Hansen T, Offen WA, Ferraz MJ, Li KY, Aerts JMFG, van der Marel GA, Codee JDC, Davies GJ, Overkleeft HS J Am Chem Soc. 2018 Apr 4. doi: 10.1021/jacs.8b02399. PMID:29601200[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Schroder SP, Wu L, Artola M, Hansen T, Offen WA, Ferraz MJ, Li KY, Aerts JMFG, van der Marel GA, Codee JDC, Davies GJ, Overkleeft HS. Gluco-1 H-imidazole: A New Class of Azole-Type beta-Glucosidase Inhibitor. J Am Chem Soc. 2018 Apr 4. doi: 10.1021/jacs.8b02399. PMID:29601200 doi:http://dx.doi.org/10.1021/jacs.8b02399
|
